Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis.
MR imaging is becoming increasingly important in the evaluation of multiple sclerosis based on its sensitivity to acute, often subclinical events in the brain and because it provides a basis for measuring the accumulation of disease over time. Contrast-enhanced MR imaging in particular evaluates disease at the fundamental level of events affecting the blood-brain barrier. This review emphasizes (a) recent developments in the use of contrast-enhanced MR imaging as a measure of disease in patient groups and individuals and (b) its emerging role in evaluating new therapies.
Simon
J H
JH
Department of Radiology, University of Colorado Health Sciences Center, Denver 80262, USA.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D002986:Clinical Trials as Topic; D003287:Contrast Media; D005069:Evaluation Studies as Topic; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D009900:Optic Nerve / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013116:Spinal Cord / Q000473:pathology; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D003287:Contrast Media